Hypertension and Heart Failure (2^nd Ed., 2nd ed. 2023) Epidemiology, Mechanisms and Treatment Updates in Hypertension and Cardiovascular Protection Series

The second edition of this well-received book will offer both new insights into the intimate mechanisms of transition from hypertension to heart failure and clinical practice advice on the prevention and treatment of heart failure in hypertensive population. Heart failure is the result of the hypertension's effects on the heart and it is a growing public health problem, as it affects  20-50% of the adult population in developed countries.

In this context the international scientific community is continuously struggling to develop better strategies in screening, diagnosing and treating hypertension and its deleterious effects. Thus, this field is continuously changing, with new important information being added constantly.   A part of the book dedicated to diagnostics, comprising a chapter on new perspectives on multimodality imaging and a special chapter on diastolic dysfunction. The arrhythmic complications of hypertensive heart disease are  discussed in two chapters on atrial fibrillation and ventricular arrhythmias respectively. Readers will also find new chapters regarding hypertension and heart failure in special populations such as cancer patients, young patients, pregnancy and patients with a history of SARS-CoV2 infection. 

This book is a useful tool for clinicians but also to the research community interested in heart failure and consequences of hypertension on heart who want to be up-to-date with the new developments in the field.

Maria Dorobantu is Professor of Cardiology at the University of Medicine and Pharmacy Carol Davila Bucharest, Romania. She has a special interest in the assessment and treatment of heart failure and arterial hypertension and has been principal investigator of important trials. She is the President of the Romanian Society of Hypertension and the national coordinator of the SEPHAR studies (Study for the Evaluation of Prevalence of Hypertension and Cardiovascular Risk among the Adult Population of Romania). Between 2016-2018 she has been the chairperson of the Coronary Pathophysiology and Microcirculation Working Group of Europeam Society of Cardiology. 
Giuseppe Mancia isProfessor Emeritus of the University of Milano and Head of the Hypertension Centre of the Instituto Clinico Universitario, Verano Brianza. He is President of the Italian Foundation on “Ricerca e Innovazione su Ipertensione e Protezione Cardiovascolare”, of the Foundation of the European Society of Hypertension (ESH) in Zurich and Chairman of the Educational Board of ESH.
He is since many years in the list of the “highly cited” scientists (Thompson Reuters) and has in 2013 been regarded as one of the 400 most influential biomedical investigators in the world (EJCI 2013).
Guido Grassi is Professor of Internal Medicine at the Dept. of Clinical Medicine of the University of Milano, director of the PhD course in "Hypertension and Cardiovascular Risk", and director of the Center of Clinical Physiology and Hypertension of the same university.
He is member of the Scientific Council on Hypertension of the ESC, ESH and ISH. He is also member of the ESH/ESC Task   Force Guidelines on the Management of Hypertension.
He is Executive Editor of “Journal of Hypertension”, official Journal of the ISH and the ESH.
Victor Voicu is currently fellow the and vice president of Romanian Academy and President ofMe

Describes new guidelines and recommendations for real-life practice with hypertensive patients Approaches newly developed pharmacological and invasive treatments of hypertensive heart failure 0ffers novel insights to the pathobiology, diagnosis and management of hypertension and heart failure